These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 1009020)

  • 1. Chelation studies with 2,3-dihydroxybenzoic acid in patients with beta-thalassaemia major.
    Peterson CM; Graziano JH; Grady RW; Jones RL; Vlassara HV; Canale VC; Miller DR; Cerami A
    Br J Haematol; 1976 Aug; 33(4):477-85. PubMed ID: 1009020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effect of 2,3-dihydroxybenzoic acid (2,3-DHB) on the elimination of iron in a patient with beta-thalassemia major].
    Jensen M; Bender Ch
    Monatsschr Kinderheilkd (1902); 1977 May; 125(5):587. PubMed ID: 876248
    [No Abstract]   [Full Text] [Related]  

  • 3. Chelation therapy in beta-thalassemia major: a one-year double blind study of 2,3-dihydroxybenzoic acid.
    Peterson CM; Graziano JH; Grady RW; Jones RL; Markenson A; Lavi U; Canale V; Gray GF; Cerami A; Miller DR
    Exp Hematol; 1979 Feb; 7(2):74-80. PubMed ID: 371974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intensive iron chelation therapy in beta-thalassemia major: some effects on iron metabolism and blood transfusion dependence.
    Silvestroni E; Bianco I; Graziani B; Lerone M; Valente M; Congedo P; Ponzini D; Costantini S
    Acta Haematol; 1982; 68(2):115-23. PubMed ID: 6812366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Puzzle of Aspirin and Iron Deficiency: The Vital Missing Link of the Iron-Chelating Metabolites.
    Kontoghiorghes GJ
    Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral iron chelation with 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron loaded thalassemia patients.
    Olivieri NF; Matsui D; Liu PP; Blendis L; Cameron R; McClelland RA; Templeton DM; Koren G
    Bone Marrow Transplant; 1993; 12 Suppl 1():9-11. PubMed ID: 8374574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one.
    Kontoghiorghes GJ; Aldouri MA; Hoffbrand AV; Barr J; Wonke B; Kourouclaris T; Sheppard L
    Br Med J (Clin Res Ed); 1987 Dec; 295(6612):1509-12. PubMed ID: 3122880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Iron overload and iron chelation therapy in thalassaemia and sickle cell haemoglobinopathies.
    Pippard MJ
    Acta Haematol; 1987; 78(2-3):206-11. PubMed ID: 3120473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. L1 (1,2-dimethyl-3-hydroxypyrid-4-one) for oral iron chelation in patients with beta-thalassaemia major.
    Töndury P; Kontoghiorghes GJ; Ridolfi-Lüthy A; Hirt A; Hoffbrand AV; Lottenbach AM; Sonderegger T; Wagner HP
    Br J Haematol; 1990 Dec; 76(4):550-3. PubMed ID: 2265118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deferasirox for managing iron overload in people with thalassaemia.
    Meerpohl JJ; Antes G; Rücker G; Fleeman N; Motschall E; Niemeyer CM; Bassler D
    Cochrane Database Syst Rev; 2012 Feb; (2):CD007476. PubMed ID: 22336831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Iron absorption in non-transfused iron loading anaemias: prediction of risk for iron loading, and response to iron chelation treatment, in beta thalassaemia intermedia and congenital sideroblastic anaemias.
    Pippard MJ; Weatherall DJ
    Haematologia (Budap); 1984; 17(1):17-24. PubMed ID: 6724353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review.
    Delea TE; Edelsberg J; Sofrygin O; Thomas SK; Baladi JF; Phatak PD; Coates TD
    Transfusion; 2007 Oct; 47(10):1919-29. PubMed ID: 17880620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A study of the mechanisms and sites of action of desferrioxamine in thalassaemia major.
    Bianco I; Graziani B; Lerone M; Congedo P; Clemente GF; Ingrao G; Ciccone F; Di Nucci GD; Mandelli F; Isacchi G
    Acta Haematol; 1984; 71(2):100-5. PubMed ID: 6421046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The identification of 2, 3-dihydroxybenzoic acid as a potentially useful iron-chelating drug.
    Graziano JH; Grady RW; Cerami A
    J Pharmacol Exp Ther; 1974 Sep; 190(3):570-5. PubMed ID: 4416298
    [No Abstract]   [Full Text] [Related]  

  • 15. Chelation therapy for the treatment of thalassemia.
    Graziano JH; Cerami A
    Semin Hematol; 1977 Jan; 14(1):127-34. PubMed ID: 318766
    [No Abstract]   [Full Text] [Related]  

  • 16. Urinary iron excretion induced by intravenous infusion of deferoxamine in beta-thalassemia homozygous patients.
    Boturao-Neto E; Marcopito LF; Zago MA
    Braz J Med Biol Res; 2002 Nov; 35(11):1319-28. PubMed ID: 12426631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Objectives and mechanism of iron chelation therapy.
    Hershko C; Link G; Konijn AM; Cabantchik ZI
    Ann N Y Acad Sci; 2005; 1054():124-35. PubMed ID: 16339658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Iron excretion in thalassemia after the administration of chelating agents.
    Markum AH; Iskandar W; Keng KL; Odang O
    Paediatr Indones; 1969; 9(3):89-98. PubMed ID: 4981722
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of Iron Chelation Therapy on Glucose Metabolism in Non-Transfusion-Dependent Thalassaemia.
    Chuansumrit A; Pengpis P; Mahachoklertwattana P; Sirachainan N; Poomthavorn P; Sungkarat W; Kadegasem P; Khlairit P; Wongwerawattanakoon P
    Acta Haematol; 2017; 137(1):20-26. PubMed ID: 27838686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of iron overload in thalassemia.
    Cianciulli P
    Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():208-13. PubMed ID: 19337180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.